All In Biotech

Drug Trial Radar · NCT02839200

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Multi-center, Double-blind, Randomized, Placebo-controlled, Active-reference, Parallel-group, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Last checked: Nov 19, 2026Latest source record: Apr 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

360

Actual

Start

Oct 4, 2016

Primary completion

Apr 12, 2017

Study completion Jun 20, 2017

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Jul 20, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.

Conditions

  • Insomnia Disorder

Interventions

  • ACT-541468 5 mgDrug

    Capsule for oral administration containing ACT-541468 at a strength of 5 mg

  • ACT-541468 10 mgDrug

    Capsule for oral administration containing ACT-541468 at a strength of 10 mg

  • ACT-541468 25 mgDrug

    Capsule for oral administration containing ACT-541468 at a strength of 25 mg

  • ZolpidemDrug

    Over-encapsulated zolpidem tablet at a strength of 10 mg

  • Placebo 1Drug

    Placebo capsules matching ACT-541468 capsules

  • Placebo 2Drug

    Placebo capsules matching over-encapsulated zolpidem

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2Time frame: Baseline and Days 1&2

Locations

35 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigator Site

    Santa Monica, California

  • Investigator Site

    Upland, California

  • Investigator Site

    Brandon, Florida

  • Investigator Site

    Clearwater, Florida

  • Investigator Site

    Coral Gables, Florida

  • Investigator Site

    DeLand, Florida

  • Investigator Site

    Hollywood, Florida

  • Investigator Site

    Miami, Florida

  • Investigator Site

    Atlanta, Georgia

  • Investigator Site

    Chicago, Illinois

  • Investigator Site

    Indianapolis, Indiana

  • Investigator Site

    Novi, Michigan

  • Investigator Site

    Las Vegas, Nevada

  • Investigator Site

    New York, New York

  • Investigator Site

    Cincinnati, Ohio

  • Investigator Site

    Berlin, Germany

  • Investigator Site

    Berlin, Germany

  • Investigator Site

    Berlin, Germany

  • Investigator Site

    Dresden, Germany

  • Investigator Site

    Hamburg, Germany

  • Investigator Site

    Hamburg, Germany

  • Investigator Site

    Hanover, Germany

  • Investigator Site

    Schwerin, Germany

  • Investigator Site

    Schwerin, Germany

  • Investigator Site

    Budapest, Hungary

  • Investigator Site

    Szeged, Hungary

  • Investigator Site

    Törökbálint, Hungary

  • Investigator Site

    Beersheba, Israel

  • Investigator Site

    Haifa, Israel

  • Investigator Site

    Barcelona, Spain

  • Investigator Site

    Barcelona, Spain

  • Investigator Site

    Madrid, Spain

  • Investigator Site

    Zaragoza, Spain

  • Investigator Site

    Gothenburg, Sweden

  • Investigator Site

    Örebro, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.